4 One such instance for which states have this flexibility is for agents when used for anorexia, weight loss, or weight gain. Hence, states that participate in MDRP are not required to cover agents for weight loss and may elect not to cover anti-obesity medications (AOMs) such as Saxenda, Wegovy, and Zepbound for their weight loss indications
Their efforts, particularly the development of AlphaFold, have had a transformative impact on the life sciences, enabling remarkable advances in understanding protein structures at scale (Hopfield and Hinton, 2024
The primary aim was to assess the impact of this combination therapy on serum hormone levels, especially IGF-1, as well as to explore whether these agents could augment the anabolic environment provided by testosterone [2]
Straight to your inbox
Krahenbuhl S, Mang G, Kupferschmidt H, Meier PJ, Krause M: Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity
Frances MD